Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Pfizer (NYSE: PFE) will host a webcast and conference call with analysts at 10:00 a.m. EDT on Tuesday, May 5, 2026 to discuss its First Quarter 2026 Performance Report. Registration and webcast access are available at www.pfizer.com/investors.
The live call can also be heard by phone (U.S./Canada: 800-456-4352; international: 785-424-1086) using passcode 74607. A transcript and replay will be posted within 24 hours and remain available for at least 90 days.
Pfizer (NYSE: PFE) and Valneva reported Phase 3 VALOR results for investigational Lyme vaccine PF-07307405 (LB6V), showing ~73–75% efficacy versus placebo in pre-specified analyses. The candidate was well tolerated with no safety concerns identified at analysis. Fewer-than-expected cases limited statistical power; Pfizer plans regulatory submissions.
Key metrics: efficacy 73.2% (28 days post-dose 4) and 74.8% (1 day post-dose 4), with wide 95% CIs. Collaboration grants Pfizer exclusive manufacturing and commercialization rights upon approval.
Pfizer (NYSE: PFE) warns shareholders to reject an unsolicited mini-tender offer by Tutanota LLC to buy up to 1,000,000 shares at $32.00 per share.
The offer equals ~0.02% of outstanding shares (as of March 9, 2026), is conditioned on the closing price exceeding $32.00, may be extended to April 13, 2026, and is subject to financing and other conditions that may not be satisfied.
Pfizer (NYSE: PFE) reported positive topline Phase 3 TALAPRO-3 results: TALZENNA plus XTANDI met the primary endpoint with a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) versus placebo plus XTANDI, exceeding the pre-specified hazard ratio target of 0.63.
Consistent benefit was seen in BRCA and non-BRCA HRR gene–mutated metastatic castration-sensitive prostate cancer; an interim analysis showed a strong trend toward improved overall survival. Results will be presented and discussed with global health authorities.
Pfizer (NYSE: PFE) reported positive topline Phase 2 FOURLIGHT-1 results for atirmociclib in HR+, HER2- metastatic breast cancer, meeting the primary endpoint with a 40% reduction in risk of progression or death (HR 0.60; 95% CI 0.440–0.825; p=0.0007).
Results were consistent across prespecified subgroups, >90% of patients started atirmociclib within three months of prior CDK4/6 inhibitor therapy, overall survival was immature (~20% events), and safety was manageable with 6.4% discontinuations due to adverse events. Phase 3 first-line study is ongoing.
Pfizer (NYSE: PFE) reported positive topline Phase 2 results for tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis, meeting the primary endpoint with statistically significant EASI-75 improvements at Week 16 across doses.
Placebo-adjusted EASI-75 at Week 16: 38.7% (low), 51.9% (middle), 49.4% (high). Pfizer plans Phase 3 initiation this year and will present detailed results at future medical meetings.
NYSE (NYSE:ICE) issued a pre-market content update on March 4, 2026, featuring market commentary and floor events.
Highlights: a March 4 pre-market briefing by Ashley Mastronardi, an NYSE Live interview with two-time Olympic gold medalist Alysa Liu, Opening Bell partners Ronald McDonald House NY, New York Rangers and RBC Capital Markets, and a Closing Bell by Pfizer (NYSE: PFE).
Pfizer (NYSE: PFE) and Astellas announced Phase 3 EV-304 results showing perioperative PADCEV plus Keytruda cut risk of recurrence/progression or death by 47% versus neoadjuvant gemcitabine+ciplatin (HR 0.53; 95% CI 0.41–0.70; 1-sided p<.0001).
Two‑year event‑free survival was estimated at 79.4% versus 66.2%; overall survival improved (HR 0.65; 95% CI 0.48–0.89; 1-sided p=0.0029) and pathological complete response reached 55.8% versus 32.5% at surgery.
ViiV Healthcare (related to PFE) presented Phase 1 and in-vitro pipeline data at CROI 2026 showing two investigational long-acting HIV therapies with potential for twice-yearly dosing.
VH184, a third-generation INSTI, showed single-dose drug levels up to six months and improved resistance profile versus bictegravir. VH499, a capsid inhibitor, was generally well tolerated and supports ultra long-acting six-month dosing; phase 2b and further studies will define dosing.
ViiV Healthcare (PFE) reported 12-month interim Phase IIb EMBRACE data showing a regimen of intravenous lotivibart (N6LS) every four months plus monthly long-acting cabotegravir maintained viral suppression in 94% (IV) and 82% (SC) of participants versus 88% on standard of care.
The study observed confirmed virologic failures of 4% (n=2/50) IV, 6% (n=3/49) SC, and 4% (n=1/26) standard of care, with lotivibart generally well tolerated and the trial progressing to evaluate a twice-yearly IV dosing interval.